<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04079192</url>
  </required_header>
  <id_info>
    <org_study_id>19-EU-01</org_study_id>
    <nct_id>NCT04079192</nct_id>
  </id_info>
  <brief_title>Biolimus A9™ (BA9™) Drug Coated Balloon (DCB) Study</brief_title>
  <acronym>REFORM</acronym>
  <official_title>A Prospective, Randomized, Non-Inferiority Trial to Determine the Safety and Efficacy of the BA9TM Drug Coated Balloon for the Treatment of In-Stent Restenosis: First-in-Man Trial (REFORM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biosensors Europe SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biosensors Europe SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a Prospective, Randomized, Non-Inferiority Trial to Determine the Safety and&#xD;
      Efficacy of the BA9™ Drug Coated Balloon for the Treatment of In-Stent Restenosis. It is a&#xD;
      First-in-Man Trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial will serve as a first-in-human (FIH) experience for the BA9™ DCB in a&#xD;
      population of patients with coronary artery disease who have an indication for interventional&#xD;
      treatment of in-stent restenosis (ISR) in a bare-metal stent (BMS) or drug-eluting stent&#xD;
      (DES).&#xD;
&#xD;
      The study uses a prospective, multi-center, single blind, randomized controlled trial design&#xD;
      to enroll 195 patients. The study will seek to prove that the BA9-DCB is non-inferior to the&#xD;
      approved CE marked Sequent Please® Paclitaxel Coated Balloon with respect to % Diameter&#xD;
      Stenosis and has similar safety characteristics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 7, 2020</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients who meet all the eligibility criteria will be randomized 2:1 to receive treatment with either a BA9-DCB or a Sequent Please® Paclitaxel Coated Balloon.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>The subject will be blinded to the study treatment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Diameter Stenosis (DS)</measure>
    <time_frame>6 months</time_frame>
    <description>Percent DS of the target segment assessed by quantitative coronary angiography (QCA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target lesion failure</measure>
    <time_frame>1 month, 6 months, 1 year and 2 years</time_frame>
    <description>Taget lesion failure defined as a composite of cardiovascular death, any target vessel myocardial infarction, coronary artery bypass graft and clinically driven target lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel failure</measure>
    <time_frame>1 month, 6 months, 1 year and 2 years</time_frame>
    <description>Target vessel failure defined as a composite of cardiovascular death, any target vessel myocardial infarction, and clinically driven target vessel revascularization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">195</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>In-Stent Restenosis</condition>
  <arm_group>
    <arm_group_label>Biolimus A9™ Drug Coated Balloon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who meet the eligibility criteria and who are randomised to this arm, will receive treatment with the Biolimus A9™ Drug Coated Balloon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequent ® Please Paclitaxel coated balloon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who meet the eligibility criteria and who are randomised to this arm, will receive treatment with the Sequent ® Please Paclitaxel coated balloon</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Biolimus A9 Drug Coated Balloon</intervention_name>
    <description>A non-surgical procedure that uses a catheter to place a semi-compliant angioplasty drug coated balloon to open up coronary arteries that have been narrowed by atherosclerosis. The balloon is inflated to treat the stenosis and transfer the drug to arterial wall, and then is deflated and withdrawn.</description>
    <arm_group_label>Biolimus A9™ Drug Coated Balloon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SeQuent Please Paclitaxel Drug Coated Balloon</intervention_name>
    <description>A non-surgical procedure that uses a catheter to place a semi-compliant angioplasty drug coated balloon to open up coronary arteries that have been narrowed by atherosclerosis. The balloon is inflated to treat the stenosis and transfer the drug to arterial wall, and then is deflated and withdrawn.</description>
    <arm_group_label>Sequent ® Please Paclitaxel coated balloon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients presenting with in-stent restenosis (ISR) and clinical symptoms of ischemia&#xD;
             and/or (i) evidence of ischemia on non-invasive testing or (ii) hemodynamically&#xD;
             relevant lesion defined by FFR ≤ 0.80 or iFR ≤ 0.89 or &gt; 90% stenosis.&#xD;
&#xD;
          -  Patient presenting with a lesion that can be fully covered with one DCB length. -&#xD;
             Patients can have up to two index lesions with ISR, which can both be treated and&#xD;
             evaluated.&#xD;
&#xD;
          -  Patient has provided written informed consent&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  Patient is willing and able to comply with the study procedures and follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient presents with a ST-elevation myocardial infarction (STEMI) or had an acute MI&#xD;
             within 48 hours prior to presentation (according to the universal definition of&#xD;
             myocardial infarction).&#xD;
&#xD;
          -  Patient with acute cardiac decompensation or acute cardiogenic shock&#xD;
&#xD;
          -  Documented left ventricular ejection fraction (LVEF) ≤ 30%&#xD;
&#xD;
          -  Patient with impaired renal function (glomerular filtration rate &lt; 80 mL/min/1.73 m2).&#xD;
&#xD;
          -  More than 2 epicardial vessels requiring revascularization&#xD;
&#xD;
          -  Significant left main stenosis (by visual estimation) or an ISR located in the left&#xD;
             main (LM).&#xD;
&#xD;
          -  Patient has an ISR lesion that cannot be covered with one DCB length.&#xD;
&#xD;
          -  Patient has an ISR in the target segment in a stent of a smaller diameter than 2.5mm.&#xD;
&#xD;
          -  Severe calcification that might prevent a sufficient expansion of the DCB, if not&#xD;
             pre-treated with rotablation or a shockwave application device.&#xD;
&#xD;
          -  Known hypersensitivity or contraindication to biolimus, paclitaxcel, aspirin,&#xD;
             thienopyridines, or iodinated contrast that cannot be pre-treated.&#xD;
&#xD;
          -  Pregnant and/or breast-feeding females or females who intend to become pregnant during&#xD;
             the time of the study.&#xD;
&#xD;
          -  Subject currently enrolled in other investigational device or drug trial in which the&#xD;
             primary endpoint has not yet been reached.&#xD;
&#xD;
          -  Anticipated difficulties to complete the angiographic follow-up study.&#xD;
&#xD;
          -  Patient with a life expectancy of less than 12 months.&#xD;
&#xD;
          -  Patients lacking mental capacity (i.e. patients suffering from dementia and others) to&#xD;
             provide informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert A Byrne, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mater Private Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Linda korthout</last_name>
    <phone>+41(0)218048000</phone>
    <phone_ext>161</phone_ext>
    <email>l.korthout@biosensors.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Keith Oldroyd, MD</last_name>
    <email>k.oldroyd@biosensors.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Heart Center, Segeberger Kliniken</name>
      <address>
        <city>Bad Segeberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tölg</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heart Center Leipzig - University of Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abdel-Wahab</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Paul Gerhardt Stift</name>
      <address>
        <city>Wittenberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kleber</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mater Private Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Byrne</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Galway</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mylotte</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Cardiologico Monzino</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabbiocchi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabate</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ortiz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de La Princesa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfonso</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth hospital</name>
      <address>
        <city>Bournemouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>O'Kane</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anderson</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Craigavon Cardiac Centre</name>
      <address>
        <city>Craigavon</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Menown</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dorset County Hospital</name>
      <address>
        <city>Dorchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Witherow</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Altnagelvin Area Hospital</name>
      <address>
        <city>Londonderry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramsewak</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Worcestershire Royal Hospital</name>
      <address>
        <city>Worcester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trevelyan</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 27, 2019</study_first_submitted>
  <study_first_submitted_qc>September 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2019</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug-Coated Balloon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Umirolimus</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

